Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
Hristova, Ivalina × Boellaard, Ronald Vogel, Wouter Mottaghy, Felix Marreaud, Sandrine Collette, Sandra Schöffski, Patrick Sanfilippo, Roberta Dewji, Raz van der Graaf, Winette Oyen, Wim #
European Journal of Nuclear Medicine and Molecular Imaging vol:42 issue:6 pages:848-857
(18)F-Labelled fluorodeoxyglucose (FDG) can detect early changes in tumour metabolism and may be a useful quantitative imaging biomarker (QIB) for prediction of disease stabilization, response and duration of progression-free survival (PFS). Standardization of imaging procedures is a prerequisite, especially in multicentre clinical trials. In this study we reviewed the quality of FDG scans and compliance with the imaging guideline (IG) in a phase III clinical trial.